T he report by Martelli et al 1 in this issue of the Annals of Surgery is a most interesting analysis of the role of axillary dissection in breast cancer. After their previous nonrandomized trial in similar patients, 2 which suggested little difference in overall survival while avoiding axillary dissection in older women, the authors conducted this randomized trial in women ages 65 to 80 years. The patients had a clinically negative axilla and all underwent quadrantectomy, Tamoxifen, and radiation therapy, but had been randomized to either dissection or observation of the axilla. No patient had sentinel node biopsy. From the randomized assignment between various presenting features, patients were well-matched with the exception of tumor size. Patients without axillary dissection had a 45% incidence of cancers Յ1 cm (T1a and T1b), whereas the axillary dissection patients had only 29% Յ1 cm. Conversely, T1c cancers constituted 63% of the axillary dissection patients, but only 47% of the observation patients. Although the authors do not state specifically whether these size differences were statistically significant, the implication is that they were not. However, considerably increased rates of node metastases occur in T1c cancers.
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In the axillary dissection arm, 23% of the patients had positive nodes of which 72% had only 1 positive node and 24% had more than 3 node metastases. The authors do not describe their histologic technique for examination of the extent of these nodal metastases. It would have been helpful to know whether lymph nodes had macrometastases, micrometastases, or metastatic cells discovered only by immunohistochemical techniques. Their reported incidence of nodal metastases corresponds with what is observed in contemporary patients with breast cancer in populations with extensive mammographic screening. 3 It would have been interesting to know the proportion of patients with mammographically discovered cancers, because size for size such patients have a lower node metastases rate and a higher survival than size-equivalent palpable cancers. Clinically, all patients were estimated to have T1 cancers (Յ2 cm), but on final pathology analysis, 7% of each group had T2 primary cancers but none exceeded 25 mm. However, T2 cancers have a considerably higher rate of node metastases. As evidence of the clinically early presentation was the fact that only 11% and 7% of patients had grade III tumors in the dissection versus observation arms.
Follow up of patients was a median of 60 and 62 months in the 2 groups and all had at least 50 months observation with longest follow up at 7 and a half years. There were very few untoward events in following these patients: 2% of each group had an in-breast local recurrence, and only 2% or 3% had a contralateral primary new primary breast cancer. In each group, only 5% developed distant metastases, and only of 4% died of breast cancer. These data substantiate the relatively early breast cancers that make up most patients seen today. 3 Two patients (2%) in the axillary observation group developed clinical axillary recurrences at a median of 16 months after diagnosis of cancer, consistent with most reports of between 18 and 24 months median interval to axillary recurrence in patients without axillary dissection. The cumulative incidence of all breast and axillary events, breast cancer mortality, and overall survival was virtually identical in the 2 groups.
The authors conclude from their data that axillary dissection in older patients treated with radiation therapy and Tamoxifen (regardless of estrogen receptor status) after quadrantectomy do not benefit from an axillary dissection. They suggest that even sentinel node biopsy is not necessary because the rate of clinical nodal recurrence (2%) is so low. Breast cancer mortality and overall mortality were not worsened after observation rather than dissection of the axillary lymph nodes despite the assumed 23% rate of axillary nodal metastases. The author's conclusion is identical to the BO-4 trial of the NSABP reported by Fisher in a 25-year analysis, 4 which also found that there was no adverse survival impact from not performing an axillary dissection in clinically nodenegative patients. That trial randomized patients among radical mastectomy, mastectomy alone, or mastectomy with radiation therapy. Fisher's conclusion was completely supported by the 25-year results of the Danish randomized trial, 5 which compared a super radical nodal resection with radical mastectomy to the McWhirter technique of simple mastectomy with observation of the axilla and only 3500-cGy radiation to the chest wall area. Survival curves at 25 years were identical in all analyzed subgroups. Several other recent randomized trials comparing axillary dissection with observation by Greco et al, 6 Zurrida et al, 7 and Louis-Sylvestre et al 8 come to the same conclusion: In early breast cancer, observation only of the axilla does not impair survival.
These 6 randomized trials 1,4 -8 lie at the heart of the continuing surgical oncology controversy regarding the therapeutic value of removing lymph nodes and lymph node metastases. Orr, 9 in a meta-analysis of earlier axillary dissection versus observation trials, concluded that there was an approximately 5% survival advantage from performing axillary dissection. The 5 studies he selected for meta-analysis were not all appropriate for contemporary breast cancer or were analyzed with too short a follow up. The early Guy's Hospital trial, carried out in the 1950s, dealt with patients with breast cancer who were far different than in this era of mammographic screening. The Institute Curie study from Paris, at 4 years, when Orr did his analysis, was reported as showing a survival advantage, but the 15-year report has recently appeared and demonstrates absolutely no survival difference, despite significant differences in axillary recurrence rates. 8 Thus, the Orr meta-analysis should be seriously questioned in the face of the 6 trials noted here, especially with the Curie Institute long-term result. 8 A recent extensive literature review by Gervasoni 10 examined the role of regional node dissection in a variety of epithelial cancers and concluded that there was no proven survival benefit in cancers of the head and neck, esophagus, lung, stomach, colorectum, breast, or melanoma from regional node dissection. These summarized reports examined cancers with a more serious prognosis than current breast cancer and concluded that there was no consistent evidence of improved survival from various degrees of regional nodal treatment ranging from observation to radical resection.
The current continued enthusiasm for lymphatic dissection to improve survival occurs at a time when lymph node metastases are becoming uncommon in patients detected by screening as with gastric cancer in Japan 11 and with breast cancer, 3 melanoma, and colorectal carcinoma in Europe and the United States. Not only is the proportion of patients with lymph node metastases lower, but the extent of lymphatic metastatic disease in the nodes is far less, and many lymph node metastases consist of micrometastases or immunohistochemically detected clusters of cells and frequently only in a single node. The 6th edition of the AJCC Staging Manual 12 notes that nodal involvement Յ0.2 mm discovered by immunohistochemistry are N 0 , indicating the unknown effect or survival of such minor nodal involvement.
Because surgeons only have a therapeutic role in primary cancer by the removal of the primary malignancy and the regional lymph nodes, the concept that these lymph nodes must be removed even if they reside at a distance from the primary (breast cancer, melanoma) is thoroughly ingrained. The concept that lymph node metastases only have an indicator role but are not governors of outcome 13 is still not widely accepted, despite increasing evidence that nodal removal, although contributing to more accurate staging and regional control, adds nothing to survival.
Extensive animal research indicates that highly specific organ-selective metastases occur at the conclusion of a highly inefficient metastatic cascade that proceeds from shedding cells from the primary cancer by intravasation into blood vessels or lymphatics, to circulation to, and lodgment on distant organ endothelium, followed by extravasation through the vessel wall, into the distant organ tissues to a state of dormancy, or in selective situations, progressive growth to a clinical metastases. 14, 15 The frequency of these cellular events has been suggested by bone marrow aspiration in patients with breast cancer. T1a and T1b breast cancers have marrow metastatic cells in 25% to 35% of patients, 16 ,17 yet have 20-year survival rates of over 95% and 90%, respectively. 18 
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Annals of Surgery • Volume 242, Number 1, July 2005 The frequency of metastatic cells is also apparent in other organs beside lymph nodes and bone marrow as noted in the transplantation literature. Organ donors who have ever had a cancer have a high rate of transmitting that cancer to the immunosuppressed recipients from the donated organ. This phenomenon has been reported in melanoma, 19 but in thoracic organ transplantation, such cancer transmission rate may approach 50%. 20, 21 Cancer transplantation accompanying organ donation has occurred from a wide variety of primary cancer sites in the donor, including lung, kidney, prostate, and cervix cancers, angiosarcoma, choriocarcinoma, and even glioblastoma. 21 These metastatic cells thus have resided in a dormant state for many years before the donation because donors must be clinically cancer-free. A recent report 22 indicated that a cured melanoma patient transmitted melanoma 16 years after the original melanoma surgery to both kidney recipients, and these obviously arose from cells dormantly residing in both donor kidneys, which grew rapidly in the immunosuppressed host by drastic alteration of the metastatic cell microenvironment.
Because lymph nodes are routinely resected and with sentinel node techniques more minutely examined, collections of individual cells, cell clusters, and micrometastases are frequently encountered. The fact that these cells may be specific to lymph nodes and unable to grow in other organs that might further the metastatic spread is documented in animal experiments. 23, 24 Experimentally, human breast cancer lymph node metastases injected into nude mice may selectively lodge in lymph nodes and not lodge or cause metastases in other organs, a demonstration of the specificity phenomenon that occurs in cancer metastases. 23, 24 Such metastatic specificity is clinically evident in liver metastases from colorectal cancer, lung metastases from sarcoma, and frequent lymph node metastases from low-risk thyroid cancer that seldom causes death. 25 Death in human cancers is entirely caused by distant vital organ metastases. Lymph nodes are not vital organs and by themselves do not cause death when involved by cancer. Therefore, there is no logic to lymph node metastases being directly associated with death from disease.
Martelli's report 1 and others 4 -8 reemphasize the fact that lymph node metastases, whether treated by regional node dissection, sentinel node biopsy, or observation, do not alter long-term survival of patients by themselves. Although the small number of cases in Martelli et al's 1 randomized trial does not allow for absolute conclusions, the results of all the 6 trials described allow Fisher's summary of the 25-year report of the BO-6 trial to be quoted 4 : "Although differences of a few percentage points cannot be excluded, the findings fail to show a significance survival advantage from removing occult positive nodes at the time of initial surgery or from radiation therapy." Perhaps we can cross the threshold of drastically rethinking the role of lymph node metastases, and the surgery of the lymphatic system, to correspond to today's patients with cancer and the many research studies that support the fact that lymph node metastases are indicators but not governors of distant vital organ metastases and survival.
